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G-RC-12
BRONCHIOLITIS OBLITERANS IN BONE MARROW TRANSPLANT RECIPIENTS IN HONG
KONG.
CL Lam. MSM Ip, WK Lam, KWT Tsang, C Ooi, AKW Lie. Department of Medicine, The University of
Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.
453 consecutive Chinese adult recipients of bone marrow transplant (BMT) (including 317 allogeneic BMT,
42 matched-unrelated donor (MUD) BMT) for haematological diseases were followed with lung function tests
before and after BMT at Days 90, 180, 360 and then annually plus additional tests if respiratory symptoms
developed or abnormal lung functions were detected. 37 patients (35 allogeneic and 2 MUD BMT) developed
significant airflow obstruction compatible with bronchiolitis obliterans, including 20 male and 17 female patients.
The haematological diagnoses at BMT were: acute myeloid leukaemia = 10, acute lymphoid leukaemia = 2,
chronic myeloid leukaemia = 22, myelodysplastic syndrome - 2, kappa-light chain myeloma. Significant
airflow obstruction was first detected on 351 ± 250 days after BMT. Most of these patients also had chronic
graft versus host disease involving the eyes, skin, liver and the gut despite having immunosuppressive therapy.
Lung function at detection of airflow obstruction were: FEV, = 2.10± 0.67 L (76± 21 % of predicted), with a fall
of 31± 19% compared to pre-BMT, FEV,/FVC = 68+ 11%, FEF25-75 = 1.47±0.76 L (37± 19% of predicted)
with a fall of 57±24% compared to pre-BMT . Mean duration of follow-up was 45±30 months. 4 patients
(11%) developed bronchiectasis after the onset of bronchiolitis obliterans as evidenced by high-resolution CT
scan of thorax. 6 patients (16%) died with progressive respiratory failure. Surviving patients have static or
worse lung functions compared to onset. In summary, there is a high incidence of bronchiolitis obliterans
(11%) in allogeneic BMT recipients. Flow rates at low lung volumes is a sensitive parameter. The airflow
obstruction remains static or deteriorate despite immunosuppressive and inhaled steroid therapy.
G-RC-13
COMBINATION OF PACLITAXEL AND CARBOPLATIN IN ADVANCED NON-SMALL CELL
LUNG CANCER (NSCLC)
Julie Wang. WK Lam, James Ho, C Yan, CL Lam, Simon Ip, FM Lam, Mary Ip, Kenneth Tsang. University
Department of Medicine, The University of Hong Kong, Hong Kong SAR
NSCLC is the major cause of cancer death in Hong Kong and almost always presents in very advanced stages
rendering curative treatment not feasible. NSCLC is increasingly being treated with chemotherapy although
there has not been consensus in the choice of currently available combinations of newer and more effective
therapy. We have, therefore, studied the response rate and safety profile of paclitaxel and carboplatin in
patients with metastatic or locally advanced NSCLC in both chemotherapy-naive and previously treated stage
III and IV patients with good performance status. Patients with major organ failure, previous malignancies,
active uncontrolled infection or definite contraindications for the use of corticosteroids were excluded. Paclitaxel
175gm/m2 as 3hr IVI and carboplatin IVI AUC=6 over 30 mins. Were given in 3-weekly intervals for 6 cycles.
Pre-medications with dexamethasone, cimetidine, and fluid hydration were given. Interim results were obtained
from 17 patients (4F) with age 59± 10.2 yrs. There were 12 adenocarcinomas and 2 undifferentiated NSCLC
3 squamous cell CA with 6 in TNM stage IIIB and 11 in stage IV. The objective partial response rate after III
course of chemotherapy occurred in 27% of patients 46% of cases had stable disease and 27% had progressive
disease after assessment for tumor size by two-dimensional measurements of chest x-rays or lymph node and
bronchoscopic assessment. 5 out of 14 patient completed 6 courses of chemotherapy. The overall response
rate is (33%), stable disease (33%) and progressive disease (33%). Adverse reactions including allergy (17%),
hepatotoxicity (6%), thrombocytopenia (12%), and neutropenia (12%). There had been no treatment-related
death. The combination of paclitaxel and carboplatin appears to be a fairly well tolerated and highly effective
regime in the treatment of advanced NSCLC. Further studies are warranted to evaluate the impact of this
combination on the median term response and survival of these unfortunate patients.
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